SGN-15 is studied in the treatment of cancer. It combines a monoclonal antibody with the anticancer drug doxorubicin. Monoclonal antibodies are substances that are made in the laboratory and that... Doxorubicin is a type of anthracycline antitumor antibiotic.
- Mechanism
- Curator reviewed
SGN-15 is a first-generation product composed of the chimeric BR96 antibody chemically joined by an acid-labile hydrazone linker to the chemotherapeutic drug doxorubicin. The antibody component binds to a Lewisy—related carbohydrate antigen that is highly expressed on many solid tumors; it internalizes rapidly and then releases the drug payload at the low pH present with the tumor cells.
- Primary indication
- Investigated for use/treatment in breast cancer, colorectal cancer, and lung cancer.Curator reviewed
- Code names
- SGN-15
What you can answer from here — as of April 02, 2025
Which companies are running trials of SGN-15, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account